Moderna's COVID vaccine gets provisional approval in Australia for use in younger kids
carmengabriela


Australia's Therapeutic Goods Administration granted provisional registration to Moderna's (NASDAQ:MRNA) mRNA COVID-19 vaccine Spikevax for children aged 6 months to 5 years.
The mRNA vaccine is a two-dose series of 25 Âµg per dose.
The company said that until now, children under six were the only age group not eligible for COVID vaccination in Australia.

Moderna noted that data from a phase 2/3 trial, dubbed KidCOVE, which was reported on March 23, showed a robust neutralizing antibody response in the 6-month to 5 years of age group after a two-dose regimen.
Preliminary efficacy analysis on PCR-confirmed cases collected during the Omicron wave showed similar efficacy estimates against Omicron in this age group, the company added.
Moderna (MRNA) said the provisional approval follows recent authorization of the vaccine in Argentina, Canada, Israel, the U.S., and Taiwan in the age group.